CU20200052A7 - Ligandos de psma para formación de imágenes y endorradioterapia que comprenden un grupo quelante conjugado mediante un grupo ligador a un inhibidor de psma - Google Patents

Ligandos de psma para formación de imágenes y endorradioterapia que comprenden un grupo quelante conjugado mediante un grupo ligador a un inhibidor de psma

Info

Publication number
CU20200052A7
CU20200052A7 CU2020000052A CU20200052A CU20200052A7 CU 20200052 A7 CU20200052 A7 CU 20200052A7 CU 2020000052 A CU2020000052 A CU 2020000052A CU 20200052 A CU20200052 A CU 20200052A CU 20200052 A7 CU20200052 A7 CU 20200052A7
Authority
CU
Cuba
Prior art keywords
psma
imaging
group
endorradiotherapy
links
Prior art date
Application number
CU2020000052A
Other languages
English (en)
Other versions
CU24677B1 (es
Inventor
Mara Parzinger
Alexander Schmidt
Hans-Jürgen Wester
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of CU20200052A7 publication Critical patent/CU20200052A7/es
Publication of CU24677B1 publication Critical patent/CU24677B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>La presente divulgación se refiere a la formación de imágenes y endorradioterapia de enfermedades que implican antígeno de membrana específico de próstata (PSMA). Se proporcionan compuestos que unen o inhiben PSMA y adicionalmente llevan al menos una fracción que es susceptible de radiomarcaje. En particular se refiere a ligandos de PSMA que comprenden un grupo quelante conjugado mediante un grupo ligador a un inhibidor de PSMA.</p>
CU2020000052A 2017-12-11 2018-12-11 Ligandos de psma para formación de imágenes y endorradioterapia que comprenden un grupo quelante conjugado mediante un grupo ligador a un inhibidor de psma CU24677B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17206510 2017-12-11
PCT/EP2018/084399 WO2019115547A1 (en) 2017-12-11 2018-12-11 Psma ligands for imaging and endoradiotherapy

Publications (2)

Publication Number Publication Date
CU20200052A7 true CU20200052A7 (es) 2021-03-11
CU24677B1 CU24677B1 (es) 2023-09-07

Family

ID=60654872

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000052A CU24677B1 (es) 2017-12-11 2018-12-11 Ligandos de psma para formación de imágenes y endorradioterapia que comprenden un grupo quelante conjugado mediante un grupo ligador a un inhibidor de psma

Country Status (30)

Country Link
US (2) US11497819B2 (es)
EP (2) EP4008359A1 (es)
JP (2) JP7317375B2 (es)
KR (1) KR20200097690A (es)
CN (2) CN116617421A (es)
AU (1) AU2018382479A1 (es)
BR (1) BR112020011727A2 (es)
CA (1) CA3078104A1 (es)
CL (1) CL2020001542A1 (es)
CR (1) CR20200241A (es)
CU (1) CU24677B1 (es)
DK (1) DK3723815T3 (es)
EC (1) ECSP20029142A (es)
ES (1) ES2914832T3 (es)
HR (1) HRP20220764T1 (es)
HU (1) HUE059083T2 (es)
IL (1) IL274072A (es)
JO (1) JOP20200135A1 (es)
LT (1) LT3723815T (es)
MX (2) MX2020005430A (es)
PE (1) PE20210456A1 (es)
PL (1) PL3723815T3 (es)
PT (1) PT3723815T (es)
RS (1) RS63279B1 (es)
SG (1) SG11202002965WA (es)
SI (1) SI3723815T1 (es)
TN (1) TN2020000072A1 (es)
UA (1) UA126413C2 (es)
WO (1) WO2019115547A1 (es)
ZA (1) ZA202003472B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005430A (es) 2017-12-11 2020-08-27 Univ Muenchen Tech Ligandos de psma para la formacion de imagenes y endorradioterapia.
CA3144094A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
CN113354707A (zh) * 2021-06-07 2021-09-07 苏州思萃同位素技术研究所有限公司 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品
WO2023173074A2 (en) * 2022-03-10 2023-09-14 The Research Foundation For The State University Of New York Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
PL2318366T3 (pl) * 2008-08-01 2017-10-31 Univ Johns Hopkins Środki wiążące PSMA i ich zastosowania
WO2010135431A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
EP3495355A1 (en) * 2013-10-18 2019-06-12 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3140282B1 (en) 2014-05-06 2019-07-10 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
HRP20240215T1 (hr) * 2016-03-22 2024-04-26 The Johns Hopkins University Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate
EP3724176B1 (en) 2017-12-11 2022-01-26 Helsinn Healthcare SA Fumarate salt of (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物
MX2020005430A (es) 2017-12-11 2020-08-27 Univ Muenchen Tech Ligandos de psma para la formacion de imagenes y endorradioterapia.

Also Published As

Publication number Publication date
US11497819B2 (en) 2022-11-15
EP4008359A1 (en) 2022-06-08
PL3723815T3 (pl) 2022-07-18
AU2018382479A1 (en) 2020-04-16
ECSP20029142A (es) 2020-09-30
LT3723815T (lt) 2022-07-25
IL274072A (en) 2020-06-30
JOP20200135A1 (ar) 2020-06-02
BR112020011727A2 (pt) 2020-11-17
MX2023005053A (es) 2023-05-17
DK3723815T3 (da) 2022-07-11
EP3723815B1 (en) 2022-04-20
CN116617421A (zh) 2023-08-22
HUE059083T2 (hu) 2022-10-28
JP2023139063A (ja) 2023-10-03
ZA202003472B (en) 2022-06-29
PE20210456A1 (es) 2021-03-08
ES2914832T3 (es) 2022-06-16
CR20200241A (es) 2020-09-21
CA3078104A1 (en) 2019-06-20
EP3723815A1 (en) 2020-10-21
US20200297876A1 (en) 2020-09-24
CN111182927A (zh) 2020-05-19
SI3723815T1 (sl) 2022-07-29
PT3723815T (pt) 2022-05-30
JP2021505532A (ja) 2021-02-18
UA126413C2 (uk) 2022-09-28
CU24677B1 (es) 2023-09-07
TN2020000072A1 (en) 2022-01-06
MX2020005430A (es) 2020-08-27
US20230122957A1 (en) 2023-04-20
RS63279B1 (sr) 2022-06-30
WO2019115547A1 (en) 2019-06-20
CL2020001542A1 (es) 2020-10-02
RU2020116158A (ru) 2022-01-13
KR20200097690A (ko) 2020-08-19
JP7317375B2 (ja) 2023-07-31
CN111182927B (zh) 2023-07-21
SG11202002965WA (en) 2020-04-29
HRP20220764T1 (hr) 2022-09-16

Similar Documents

Publication Publication Date Title
CU20200052A7 (es) Ligandos de psma para formación de imágenes y endorradioterapia que comprenden un grupo quelante conjugado mediante un grupo ligador a un inhibidor de psma
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CU20190109A7 (es) Moléculas de anticuerpo que se unen a cd73
DOP2018000280A (es) Compuestos moduladores de fxr (nr1h4)
UY33850A (es) Anticuerpos anti ? cd38
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
BR112016010927A2 (pt) Conjugado de fórmula
PE20160190A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
CL2020002539A1 (es) Anticuerpos multiespecíficos anti-hla-g y utilización de los mismos
CY1123790T1 (el) Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη
CU20210096A7 (es) Moléculas de unión a cd19
PE20210442A1 (es) Anticuerpos para radionuclidos quelados
CR20190193A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
UY35321A (es) Compuestos de quelatos de metales para la unión a la glicoproteína iib/iiia específica de plaquetas
CL2023000701A1 (es) Anticuerpos que se unen a il1rap y usos de los mismos
CO2022001021A2 (es) Anticuerpos que se unen a células cancerosas yque dirigen radionucleidos a dichas células
AR120093A1 (es) Anticuerpos anti-ceacam y usos de los mismos
CL2018002946A1 (es) Métodos para elaborar formulaciones nutricionales.
AR124605A2 (es) Anticuerpos anti-il-36r
AR120015A1 (es) Conjugados terapéuticos
AR102030A1 (es) Métodos para tratar enfermedades del hígado
AR095761A1 (es) Compuestos de dihidropirido pirimidina